GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine–induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, GLP-1RAs have demonstrated considerable therapeutic promise in animal models of both PD and AD.427–429”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to its effects on metabolic regulation, GLP-1, when synthesized within the brain, exhibits neuroprotective properties.397,427,431”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 10×
“These and other actions are mediated through the G protein-coupled GLP-1R, and Ex-4 has demonstrated therapeutic value in T2DM (7).”
BackgroundMethodInfluentialDiabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“GLP-1R mRNA occurs widely throughout the brains of rodents (9) and humans (6,7,10), and both GLP-1 and Ex-4 can readily enter the brain (11) to modify feeding and satiety (12).”
BackgroundJavitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263 · cited 2×
“Administration of MPTP in mice induces a consistent dopaminergic cell loss that parallels many aspects of PD (16,20).”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 3×
“Although T2DM now occurs more often in the young, the incidence rises dramatically with age, along with that of many of other conditions, including acute and chronic neurologic disorders, exemplified by stroke (2), Parkinson’s disease (PD) and Alzheimer’s disease (AD) (3,4), which, like T2DM, were once considered rela…”
BackgroundD'Mello, S. R., Galli, C., Ciotti, T., & Calissano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10989 · Cited by 892 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“These neurotrophic/protective actions are in accordance with previous findings establishing that GLP-1R stimulation protects hippocampal neurons from amyloid- peptide–, Fe2 -, and glutamate-induced toxicity (15,32,33).”
BackgroundResultInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Mattson, M. P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00275.x · Cited by 751 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
BackgroundSelf-citationCell death in the nervous system
Bredesen, D. E., Rao, R. V., & Mehlen, P. (2006) · Nature · doi:10.1038/nature05293 · Cited by 636 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
Background
Research works printed but not linked: 2
- R Sicree, J Shaw, P Zimmet Diabetes Atlas, ed D Gan (International Diabetes Federation, 3rd Ed, Brussels), pp. 15–103 (2006).
- 10.1210/endo.140.3.6550 · doi:10.1210/endo.140.3.6550 · Paper page
Cited by
Items 301–400 of 629
Yoshino, Y., Ishisaka, M., Tsujii, S., Shimazawa, M., & Hara, H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.098 · Cited by 36
Voss, U., Sand, E., Hellström, P. M., & Ekblad, E. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-30 · Cited by 36
“A number of observations also indicate that GLP1 is neuroprotective in the central nervous system [8] and clinical trials on patients with Parkinsons disease are announced [9].”
BackgroundGlucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Extra-pancreatic effects of incretin-based therapies
Gallwitz, B. (2014) · Endocrine · doi:10.1007/s12020-014-0223-0 · Cited by 35
Dunbar, M., de la Tremblaye, P. B., Azogu, I., & Plamondon, H. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.10.010 · Cited by 35
Bader, M., Li, Y., Lecca, D., Rubovitch, V., Tweedie, D., Glotfelty, E., Rachmany, L., Kim, H. K., Choi, H.-I., Hoffer, B. J., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.023 · Cited by 34
“, 2018) as well as degenerative disorders such as AD, PD, multiple system atrophy, ALS, Huntington’s disease and peripheral neuropathy (Athauda and Foltynie, 2018; Athauda and Foltynie, 2016; Bassil et al., 2017; Bertilsson et al., 2008; Harkavyi and Whitton, 2010; Hölscher, 2018; Kim et al., 2017; Li et al., 2012; Li…”
BackgroundResultSelf-citationArbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 34
Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats
Fujita, S., Ushio, S., Ozawa, N., Masuguchi, K., Kawashiri, T., Oishi, R., & Egashira, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141921 · Cited by 34
Zhang, Y., Qian, P., Zhou, H., Shen, R., Hu, B., Shen, Y., Zhang, X., Shen, X., Xu, G., & Jin, L. (2018) · Kidney & Blood Pressure Research · doi:10.1159/000492409 · Cited by 34
DPP-4 Inhibition and Neuroprotection: Do Mechanisms Matter?
Shannon, R. P. (2013) · Diabetes · doi:10.2337/db12-1794 · Cited by 34
“The use of transient MCA occlusion models has shown that both pretreatment and posttreatment with the GLP-1 receptor agonist exendin-4 provides beneficial effects on infarct size, and these benefits are abolished in GLP-1 receptor knockout mice (12,13).”
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 34
“…satiety, energy expenditure, reward pathway modulation, neuroprotection, learning and stress (Larsen et al. 1997b, Rinaman, 1999, During et al. 2003, Bertilsson et al. 2008, Li et al. 2009, Martin et al. 2009, Gil-Lozano et al. 2010, McClean et al. 2011, Aviles-Olmos et al. 2013, Lockie, 2013).”
BackgroundAbuirmeileh, A., Harkavyi, A., Rampersaud, N., Lever, R., Tadross, J. A., Bloom, S. R., & Whitton, P. S. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01394.x · Cited by 31
“and confirmed more recently by Li et al.([8]) using knockout mice for the GLP-1 receptor (GLP-1R).”
BackgroundKoshal, P., & Kumar, P. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1890-4 · Cited by 33
Li, Y., Wu, K.-J., Yu, S.-J., Tamargo, I. A., Wang, Y., & Greig, N. H. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.010 · Cited by 33
Self-citationMa, D., Liu, X., Liu, J., Li, M., Chen, L., Gao, M., Xu, W., & Yang, Y. (2019) · Brain Research · doi:10.1016/j.brainres.2019.02.030 · Cited by 33
Protection of exenatide for retinal ganglion cells with different glucose concentrations
Fu, Z., Kuang, H., Hao, M., Gao, X., Liu, Y., & Shao, N. (2012) · Peptides · doi:10.1016/j.peptides.2012.06.006 · Cited by 32
Tu, X.-K., Chen, Q., Chen, S., Huang, B., Ren, B., & Shi, S.-S. (2020) · Inflammation · doi:10.1007/s10753-020-01344-4 · Cited by 32
“GLP-1 and its analogs can move across the blood-brain barrier and bind to the GLP-1 receptor (GLP-1R), then play a crucial role in control of neuronal structure and function, even neuroprotective effects [4, 5].”
BackgroundYang, J., Lin, Y.-T., Chen, W., Yang, Y., Sun, S., & Chen, S. (2020) · Biology · doi:10.3390/biology9110348 · Cited by 32
Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
Stott, S., Wyse, R. K. H., & Brundin, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653377 · Cited by 32
Drug repurposing strategies of relevance for Parkinson’s disease
Fletcher, E. J. R., Kaminski, T. W., Williams, G. H., & Duty, S. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.841 · Cited by 32
Ostroumova, O. D., Surkova, E. V., Chikh, E. V., Rebrova, E. V., & Borisov, M. S. (2018) · Diabetes Mellitus · doi:10.14341/dm9660 · Cited by 32
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 31
“Furthermore, some authors also found that MPTP-treated mice, another typical PD mice model, were protected by exendin-4 (Li et al., 2009), Val(8)GLP-1-glu-PAL (Zhang et al., 2015a), liraglutide (Liu et al., 2015a), lixisenatide (Liu et al., 2015a), and geniposide (Chen et al., 2015b) against…”
BackgroundSelf-citationZhang, Z., Li, H., Su, Y., Ma, J., Yuan, Y., Yu, Z., Shi, M., Shao, S., Zhang, Z., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.814430 · Cited by 31
“, liraglutide, exenatide, or lixisenatide, showed neuroprotective properties in the 1-Methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model (Li et al., 2009; Liu et al., 2015; Yuan et al., 2017; Chen et al., 2018; Lin et al., 2021), and liraglutide is currently being tested in a phase II trial in PD patients (c…”
BackgroundHao, M., Kuang, H., Fu, Z., Gao, X., Liu, Y., & Deng, W. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.04.009 · Cited by 31
GLP-1R activation for the treatment of stroke: Updating and future perspectives
Darsalia, V., Nathanson, D., Nyström, T., Klein, T., Sjöholm, Å., & Patrone, C. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9285-9 · Cited by 31
Li, Y., Glotfelty, E. J., Namdar, I., Tweedie, D., Olson, L., Hoffer, B. J., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113113 · Cited by 29
Self-citationCui, S.-S., Feng, X.-B., Zhang, B.-H., Xia, Z.-Y., & Zhan, L.-Y. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.272620 · Cited by 30
“GLP-1R is widely expressed in the cerebrum, including in the cerebral cortex, substantia nigra, and hippocampus (Li et al., 2009).”
BackgroundHölscher, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01226-z · Cited by 30
Tweedie, D., Rachmany, L., Kim, D. S., Rubovitch, V., Lehrmann, E., Zhang, Y., Becker, K. G., Perez, E., Pick, C. G., & Greig, N. H. (2016) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2016.02.003 · Cited by 30
“models of AD and Parkinson’s disease (Perry et al., 2002; Perry 2003; Li et al., 2009; Li et al., 2010; Wang et al., 2015; Xu et al., 2015), and has been shown to be beneficial across multiple”
Self-citationPardridge, W. M. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1276376 · Cited by 30
The emergence of multiscale connectomics-based approaches in stroke recovery
Latifi, S., & Carmichael, S. T. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.01.003 · Cited by 30
Protective effect of rhGLP-1 (7–36) on brain ischemia/reperfusion damage in diabetic rats
Zhao, L., Xu, J., Wang, Q., Qian, Z., Feng, W., Yin, X., & Fang, Y. (2015) · Brain Research · doi:10.1016/j.brainres.2015.01.014 · Cited by 30
Sun, H. J., Knippenberg, S., Thau, N., Ragancokova, D., Körner, S., Huang, D., Dengler, R., Döhler, K. D., & Petri, S. (2012) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-012-9900-9 · Cited by 30
Dong, W., Miao, Y., Chen, A., Cheng, M., Ye, X., Song, F., & Zheng, G. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.045 · Cited by 29
Fessel, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133729 · Cited by 30
“GLP-1R mRNA expression was also seen in both cultured, embryonic primary cerebral cortical neurons and ventral mesencephalic (dopaminergic) neurons, both of which are vulnerable to hypoxia-and 6-hydroxydopamine-induced cell death, from which GLP-1 conferred protection [15].”
BackgroundHallaj, S., Halfpenny, W., Chuter, B., Weinreb, R. N., Baxter, S. L., & Cui, Q. N. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.08.030 · Cited by 29
Characterization of oromotor and limb motor dysfunction in the DJ1 -/- model of Parkinson disease
Yang, K. M., Blue, K. V., Mulholland, H. N., Kurup, M., Kelm‐Nelson, C. A., & Ciucci, M. R. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.10.036 · Cited by 29
“However, there are also a number of neuroendocrine abnormalities found in patients with PD, specifically in hormones related to eating such as ghrelin [32] and glucagon-like peptide 1 [33].”
Guttuso, T. J., Andrzejewski, K. L., Lichter, D. G., & Andersen, J. K. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.05.016 · Cited by 29
Zhang, J., Yi, T., Cheng, S., & Zhang, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106715 · Cited by 29
Research on developing drugs for Parkinson's disease
Zhang, C., Han, Q.-W., Chen, N., & Yuan, Y. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.12.017 · Cited by 29
Liu, C., Sun, S., Xie, J., Li, H., Li, T., Wu, Q., Zhang, Y., Bai, X., Wang, J., Wang, X., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02811-9 · Cited by 28
“It has been implied that EX-4 can alleviate ischemia–reperfusion injury by suppressing oxidative stress and inflammatory reaction in the mouse MCAO model [12, 14, 43, 44].”
BackgroundEngineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Tang, J., Pei, Y., & Zhou, G. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.04.013 · Cited by 28
“Recently, GLP-1 receptor (GLP-1R) expression has also been identified mainly in the neuronal population (Li et al., 2009).”
Labandeira, C. M., Bau, A. F., Ron, D. A., Muñoz, A., Losada, G. A., Koukoulis, A., Romero-López, J., & Rodriguez-Perez, A. I. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100914 · Cited by 28
Ahmad, K., Shaikh, S., Lim, J. H., Ahmad, S. S., Chun, H. J., Lee, E. J., & Choi, I. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115642 · Cited by 28
Yu, S., Wang, Y., Shen, H., Bae, E.-K., Li, Y., Sambamurti, K., Tones, M. A., Zaleska, M. M., Hoffer, B. J., & Greig, N. H. (2024) · GeroScience · doi:10.1007/s11357-024-01116-0 · Cited by 28
“This hypothesis is supported by preclinical studies of incretin mimetics across cellular and animal models of dopaminergic cell loss and PD [35, 61, 62] and, additionally, by the successful efficacy of the GLP-1 receptor agonist Exenatide in patients with moderate PD [26–30].”
MethodInfluentialSelf-citationGLP‐1 improves neuropathology after murine cold lesion brain trauma
DellaValle, B., Hempel, C., Johansen, F. F., & Kurtzhals, J. A. L. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.99 · Cited by 27
“In a murine stroke model, GLP-1 treatment demonstrated a similar reduction (~50%) on infarct volume.(5) Acute pathology leading to mitochondrial loss of function was already observed at day 1 with markedly increased ROS/RNS levels.”
BackgroundGejl, M., Rungby, J., Brock, B., & Gjedde, A. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12240 · Cited by 27
Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia
Zhang, H., Meng, J., Li, X., Zhou, S., Qu, D., Wang, N., Jia, M., Ma, X., & Xiaoxing, L. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.01.010 · Cited by 28
“GLP-1 receptor activation exerts a neuroprotective effect in cerebral ischemia (Li et al., 2009), modulates neuronal activity, protects against neuronal damage induced by various insults, and is involved in learning and memory (Greig et al.”
BackgroundTawfik, M. K., & Mohamed, M. I. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.05.005 · Cited by 28
Abdellatif, R., Heeba, G. H., Taye, A., & Khalifa, M. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.045 · Cited by 28
Lietzau, G., Magni, G., Kehr, J., Yoshitake, T., Candeias, E., Duarte, A. I., Pettersson, H., Skogsberg, J., Abbracchio, M. P., Klein, T., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.01.004 · Cited by 28
Kopp, K. O., Li, Y., Glotfelty, E. J., Tweedie, D., & Greig, N. H. (2024) · Biomolecules · doi:10.3390/biom14070872 · Cited by 27
“…abuse [5], and diseases/disorders of the brain with an inflammatory component, such as traumatic brain injury (TBI) [6,7], ischemic stroke [8,9], idiopathic intracranial hypertension [10], and neurodegenerative diseases including Alzheimer’s (AD) [11,12] and Parkinson’s diseases (PD)…”
BackgroundSelf-citationMyeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 27
Muller, C., Cheung, N. W., Dewey, H. M., Churilov, L. P., Middleton, S., Thijs, V., Ekinci, E. I., Levi, C. R., Lindley, R. I., Donnan, G. A., et al. (2018) · International Journal of Stroke · doi:10.1177/1747493018784436 · Cited by 27
Zhu, C., Li, H., Kong, X., Wang, Y., Sun, T., & Wang, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.819470 · Cited by 26
Self-citationIncretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 26
“In the transient middle cerebral artery occlusion model, exendin-4 treatment reduces infarct size and improves functional outcomes at 2 days post-stroke 158,179 .”
Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders
Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 26
Unraveling Berberine's Molecular Mechanisms in Neuroprotection Against Neurodegeneration
Begh, M. Z. A., Amin, M. A., Shatu, M. M., Sweilam, S. H., Puri, S., Ramesh, R. B., Arjun, U. V. N. V., Shanmugarajan, T. S., Pommala, N., Durairaj, A., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500170 · Cited by 26
Old wines in new bottles: Repurposing opportunities for Parkinson's disease
Kakkar, A. K., Singh, H., & Medhi, B. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.023 · Cited by 26
Tseng, Y., Tsai, Y., Fülöp, F., Chang, F., & Lo, Y. (2019) · Molecules · doi:10.3390/molecules24122249 · Cited by 26
“Increasing studies have characterized the neuroprotective role of GLP-1R in cellular and animal models of PD using pharmacological management [25,26].”
BackgroundFang, Y., Jiang, D., Wang, Y., Wang, Q., Lv, D., Liu, J., & Liu, C. (2018) · Drug Development Research · doi:10.1002/ddr.21439 · Cited by 21
“models of both Parkinson's disease (PD) and ischemic stroke (Li et al., 2009; Li et al., 2010).”
BackgroundSelf-citationHölscher, C. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000087 · Cited by 25
The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders
Yang, J., Chen, W., & Chen, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091861 · Cited by 25
“In the MPTP-induced PD mouse model, EX-4 treatment protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function [144].”
BackgroundReed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
“272 Exendin-4 also promoted apoptotic resistance and improved viability in NSC19 neuronal cells (a mouse cell line) during oxidative stress.”
Attenuated Postprandial GLP-1 Response in Parkinson’s Disease
Manfready, R. A., Engen, P. A., Verhagen Metman, L., Sanzo, G., Goetz, C. G., Hall, D. A., Forsyth, C. B., Raeisi, S., Voigt, R. M., & Keshavarzian, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.660942 · Cited by 19
Gut-Brain Communication in Parkinson’s Disease: Enteroendocrine Regulation by GLP-1
Manfready, R. A., Forsyth, C. B., Voigt, R. M., Hall, D. A., Goetz, C. G., & Keshavarzian, A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01196-5 · Cited by 24
Zhang, W., Dong, X., & Huang, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106787 · Cited by 24
Exendin‐4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease
Verma, A., Chaudhary, S., Solanki, K., Goyal, A., & Yadav, H. N. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14426 · Cited by 24
Antidiabetic treatment, stroke severity and outcome
Magkou, D., & Τζιόμαλος, Κ. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i2.84 · Cited by 24
Wu, P., Zhao, Y., Zhuang, X., Sun, A., Zhang, Y., & Ni, Y. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.08.012 · Cited by 24
Structural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson’s Disease
Sancandi, M., Schul, E. V., Economides, G., Constanti, A., & Mercer, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00479 · Cited by 24
Li, Y., Vaughan, K. L., Tweedie, D., Jung, Y. J., Kim, H. K., Choi, H.-I., Kim, D. S., Mattison, J. A., & Greig, N. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-53356-2 · Cited by 24
Self-citationLim, J., Lee, J.-J., Park, S.-H., Park, J.-H., Kim, S., Cho, H., Baek, W., Kim, D.-K., & Song, D. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.05.017 · Cited by 24
Zhang, Z., Shi, M., Li, Z., Ling, Y., Zhai, L., Yuan, Y., Ma, H., Li, H., Li, Z., Zhang, Z., et al. (2023) · Parkinson s Disease · doi:10.1155/2023/7427136 · Cited by 23
“Exendin-4 can cross the BBB well and showed good efects in animal models of PD [27, 60] and in the clinic [14, 61].”
BackgroundTreatment implications of the altered cytokine-insulin axis in neurodegenerative disease
Clark, I. A., & Vissel, B. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.030 · Cited by 23
Deselms, H., Maggio, N., Rubovitch, V., Chapman, J., Schreiber, S., Tweedie, D., Kim, D. S., Greig, N. H., & Pick, C. G. (2016) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2016.02.002 · Cited by 23
Self-citationLi, H., Cao, L., Ren, Y., Jiang, Y., Xie, W., & Li, D. (2017) · Bioscience Reports · doi:10.1042/bsr20171284 · Cited by 23
Tian, M.-J., Wang, R., Hölscher, C., Mi, R., Yuan, Z., Li, D., & Xue, G. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.05.008 · Cited by 23
Singh, A., Zapata, R. C., Pezeshki, A., Workentine, M. L., & Chelikani, P. K. (2019) · The FASEB Journal · doi:10.1096/fj.201801627rrr · Cited by 23
Exendin-4 for Parkinson's disease
Esparza-Salazar, F. D. J., Lezama-Toledo, A. R., Rivera-Monroy, G., & Borlongan, C. V. (2021) · Brain Circulation · doi:10.4103/bc.bc_21_21 · Cited by 22
“Similarly, administration of exendin 4 into the lateral ventricle has also been reported to be effective in mitigating the loss of THir neurons, preserve DA levels in the SNc, and improving the behavioral function of mice receiving MPTP.[12] This GLP‐1R‐mediated protection effect has been widely found across animal mo…”
BackgroundYu, S., Chen, S., Yang, Y.-Y., Glotfelty, E. J., Jung, Y. J., Kim, H.-K., Choi, H.-I., Choi, D., Hoffer, B. J., Greig, N. H., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00785 · Cited by 22
Self-citationNeuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson’s Disease Mouse Model
Zhang, Z., Li, H., Shi, M., Yu, Z., Shao, S., Yuan, Y., Zhang, Z., & Hölscher, C. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202318 · Cited by 22
Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., & Whitton, P. S. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02100.x · Cited by 22
“GLP-1 receptor stimulation has previously been shown to promote neuronal restoration/protection in two in vivo rodent models of PD (Bertilsson et al., 2008; Harkavyi et al., 2008; Kim et al., 2009; Li et al., 2009).”
BackgroundRetractedZhou, J., Keenan, M. J., Keller, J. N., Fernandez‐Kim, S. O., Pistell, P. J., Tulley, R. T., Raggio, A. M., Shen, L., Zhang, H., Martin, R. J., et al. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100521 · Cited by 22
“Finally, GLP-1 preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinson’s disease [31].”
Human Glucose Transporters in Health and Selected Neurodegenerative Diseases
Szablewski, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157392 · Cited by 21
“Exenatide halts cognitive decline in animal models of AD [297,298] and improves degeneration of dopaminergic neurons and motor function in PD animal models [289,299].”
Raut, S., & Cucullo, L. (2025) · Antioxidants · doi:10.3390/antiox14121490 · Cited by 21
Kuthati, Y., Rao, V. N., Busa, P., & Wong, C. (2021) · Antioxidants · doi:10.3390/antiox10091438 · Cited by 21
Mattson, M. P. (2017) · Wiley eBooks · doi:10.1002/9781118661895.ch4 · Cited by 21
Self-citationIncretins today: multiple effects and therapeutic potential
Васильевна, Ц. О., Васильевна, В. В., & As, A. (2019) · Diabetes Mellitus · doi:10.14341/dm9841 · Cited by 22
Hung, Y., Wang, Y., & Lee, S. (2020) · The FASEB Journal · doi:10.1096/fj.201902818r · Cited by 21
Self-citationRationale for ozone-therapy as an adjuvant therapy in COVID-19: a narrative review
Villani, E. R., Ranaldi, G. T., & Franza, L. (2020) · Medical Gas Research · doi:10.4103/2045-9912.289462 · Cited by 21
Mehta, K., Behl, T., Kumar, A., Uddin, M. S., Zengin, G., & Arora, S. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721999201208195901 · Cited by 21
Noguchi, T., Katoh, H., Nomura, S., Okada, K., & Watanabe, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1342944 · Cited by 20
Targeting G Protein-Coupled Receptors in the Treatment of Parkinson’s Disease
Jones-Tabah, J. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167927 · Cited by 20
Prospects of antidiabetic drugs in the treatment of neurodegenerative disease
Hu, L., Wang, W., Chen, X., Bai, G., Ma, L., Yang, X., Shu, Q., & Li, X. (2024) · Brain‐X · doi:10.1002/brx2.52 · Cited by 20
Messak, M., Abdelmageed, A., Senbel, A. A., Khattab, Y. A., Mandour, Y., Shaker, O., Rehan, A. H., Oransa, S., Nasr, M., Shabeeb, A. E., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03932-3 · Cited by 20
“In another study on a mouse model, they had the ability to improve motor function and protect neurons against degeneration (Li et al. 2009).”
Yu, Y.-W., Hsueh, S., Lai, J.-H., Chen, Y., Kang, S.-J., Chen, K., Hsieh, T.-H., Hoffer, B. J., Li, Y., Greig, N. H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041153 · Cited by 20
“The activation of the GLP-1R on neurons induces potent neurotrophic and neuroprotective actions in cellular and animal models of neural injury and neurodegeneration [5–10], including models of PD [7,11,12].”
BackgroundSelf-citationGupta, A. K., Pokhriyal, R., Khan, M. I., Kumar, D. R., Gupta, R., Chadda, R. K., Ramachandran, R., Goyal, V., Tripathi, M., & Hariprasad, G. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s214217 · Cited by 20
Khan, N. M., Ahmad, A., Tiwari, R., Kamal, M. A., Mushtaq, G., & Ashraf, G. M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141023160448 · Cited by 20
Metadata
- Authors
- Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., Brossi, A., Lahiri, D. K., Mattson, M. P., Hoffer, B. J., Wang, Y., & Greig, N. H.
- Affiliations
- National Institute on Aging (US)
- Medical University of South Carolina (US)
- National Institute on Drug Abuse (US)
- University of North Carolina at Chapel Hill (US)
- Indiana University School of Medicine (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-01-27
- Volume
- 106
- Issue
- 4
- Pages
- 1285-1290
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2633544
- OpenAlex
- W2080785707
- Cited by
- 589
- References
- 45
- Citations by year
- 2026: 18 · 2025: 39 · 2024: 39 · 2023: 24 · 2022: 33 · 2021: 49 · 2020: 41 · 2019: 40 · 2018: 43 · 2017: 34 · 2016: 41 · 2015: 45 · 2014: 34 · 2013: 33 · 2012: 27
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- University of Toronto
- National Institutes of Health
- National Institute on Aging
- National Institute on Drug Abuse
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- GLP-1 receptor, exendin-4, stroke, Parkinson's disease, dopaminergic neurons, cortical neurons, neuroprotection, MPTP mouse model, middle cerebral artery occlusion, 6-hydroxydopamine, hypoxia, oxidative stress, dopamine levels, motor function
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Cells, Cultured, Cerebral Cortex, Disease Models, Animal, Dopamine, Embryo, Mammalian, Gene Expression Regulation, Humans, Mesencephalon, Neurons, Parkinson Disease, Peptides, Venoms, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Cell Hypoxia, Treatment Outcome, Cell Death, Receptors, Glucagon, Cytoprotection, Brain Infarction, Stroke, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.